Effect of Benralizumab in Atopic Dermatitis

NCT03563066 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Dermatitis, Atopic
Dermatitis
Eczema
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases

Interventions

DRUG: Benralizumab
DRUG: Placebo Control

Sponsor

McMaster University

Collaborators

[object Object]